In a dose range of 400 mg to 1200 mg, maximum plasma concentrations increased and clearance decreased in a non dose-proportional manner. With increasing doses, the elimination half-life also became prolonged. Indications For the symptomatic relief of depressive illness. Contraindications In patients with a known hypersensitivity to the drug. Moclobemide is also contraindicated in patients in an acute confusional state.
Data involving other tricyclic antidepressants is limited.
Consequently, the concomitant use of moclobemide and tricyclic antidepressants is contraindicated. Clinical data are not available on the concomitant use of moclobemide and selective serotonin reuptake inhibitors or other available MAO inhibitors. Therefore, until such data becomes available, moclobemide should not be administered in combination with these agents. There is no experience with the concomitant use of moclobemide and narcotics. However, death has occurred in patients receiving a nonreversible, nonselective MAO inhibitor and meperidine given concomitantly.